Journal of Clinical Oncology, Vol 16, 3788-3795, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group

F Davi, HJ Delecluse, P Guiet, J Gabarre, A Fayon, O Gentilhomme, P Felman, C Bayle, F Berger, J Audouin, PA Bryon, J Diebold and M Raphael
Departement d'Hematologie and Unite Recherche Associee du Centre National de la Recherche Scientifique 625, Hopital Pitie-Salpetriere, Paris, France. fdavi@pasteur.fr

PURPOSE: Burkitt-like lymphoma (BLL) is a tumor with morphologic features intermediate between Burkitt's lymphoma (BL) and large-cell lymphoma, but its relationship with these lymphomas is currently unclear. We have therefore analyzed its characteristics within a large series of human immunodeficiency virus (HIV)-associated lymphomas. MATERIALS AND METHODS: Clinical, histologic, immunophenotypic, and molecular analyses were performed on 103 patients with AIDS lymphomas. RESULTS: Nineteen cases (18.4%) were identified as BLL. They were monoclonal B-cell proliferations, as evaluated by immunoglobulin (Ig) gene rearrangement analyses, and had rearrangement of the c-myc oncogene in 68% of cases but not the bcl-2 gene, in contrast to a previous study on non-HIV-associated BLL. This molecular pattern was therefore identical to that of typical BL, suggesting that they represented tumors of similar origin. However, some features could clearly differentiate BLL from BL and were similar to those seen in the diffuse large-cell immunoblastic lymphomas (DLC-IBL) group. These included a greater frequency of Epstein-Barr Virus (EBV) infection (79% v 48%, P = .04), an upregulation of CD39 (50% v 0%, P = .0007) and CD70 (75% v 15%, P = .003) activation antigens and of the CD11a/LFA-1 adhesion molecule (83% v30%, P = .05), and, finally, a lower CD4 count (mean, 119/microL v 270/microL, P = .04). CONCLUSION: BLL is a frequent entity among AIDS lymphomas and should be considered as a morphologic variant of BL in the context of severe immunodepression that occurs in HIV-infected patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas Mol. Cancer Ther., December 1, 2005; 4(12): 2037 - 2044. [Abstract] [Full Text] [PDF]

				K. A. Blum, G. Lozanski, and J. C. Byrd Adult Burkitt leukemia and lymphoma Blood, November 15, 2004; 104(10): 3009 - 3020. [Abstract] [Full Text] [PDF]

				M. P. Thompson and R. Kurzrock Epstein-Barr Virus and Cancer Clin. Cancer Res., February 1, 2004; 10(3): 803 - 821. [Abstract] [Full Text] [PDF]

				C. Besson, A. Goubar, J. Gabarre, W. Rozenbaum, G. Pialoux, F.-P. Chatelet, C. Katlama, F. Charlotte, B. Dupont, N. Brousse, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood, October 15, 2001; 98(8): 2339 - 2344. [Abstract] [Full Text] [PDF]

				R. F. Little, M. Gutierrez, E. S. Jaffe, A. Pau, M. Horne, and W. Wilson HIV-Associated Non-Hodgkin Lymphoma: Incidence, Presentation, and Prognosis JAMA, April 11, 2001; 285(14): 1880 - 1885. [Abstract] [Full Text] [PDF]

				J. L. Hecht and J. C. Aster Molecular Biology of Burkitt's Lymphoma J. Clin. Oncol., November 1, 2000; 18(21): 3707 - 3721. [Abstract] [Full Text] [PDF]